Alcobra Announces Positive Phase IIb Trial Results Of MG01CI - Quick Facts

(RTTNews) - Alcobra Ltd. (ADHD), Monday reported significant positive results from a Phase IIb clinical trial of its non-stimulant drug candidate MG01CI in adults with Predominantly Inattentive Attention Deficit Hyperactivity Disorder or PI-ADHD. The primary outcome of the trial was the change from baseline of the Test of Variables of Attention or TOVA ADHD score.

In an intent-to-treat analysis of the primary endpoint, the study demonstrated a statistically significant change from baseline for MG01CI 1,400 mg compared with placebo on the TOVA ADHD score.

Jonathan Rubin, the Chief Medical Officer, commented, "The statistical significance and magnitude of effect in this study replicate and confirm the TOVA findings observed in our previous placebo-controlled Phase IIb trial with MG01CI in 120 adults with ADHD. There are now two placebo-controlled Phase II studies that demonstrate the significant efficacy and tolerability attributes of MG01CI in adults with ADHD."